证券日报网讯 2月9日，信濠光电发布公告称，公司第三届董事会任期至 2026 年 2 月届满。鉴于公司董 事会换届工作尚在筹备中，为确保公司董事会工作的连续性和稳定性，公司董事会换届选举工作将适当 延期，董事会各专门委员会及高级管理人员的任期亦将相应顺延。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 2月9日，宁德时代在互动平台回答投资者提问时表示，公司及时追踪重要原材料市场供 求和价格变动，保障原材料供应及优化采购成本，并通过长协、预付款等多种措施保障供应链安全及稳 定，平滑成本波动。 ...

证券日报网讯 2月9日，菱电电控在互动平台回答投资者提问时表示，近年公司依托技术和产品，积极 拓展海外市场，成功进入部分海外主机厂客户的供应链体系，并深度参与部分国内主机厂的海外本地化 项目，但目前处于开拓阶段，占公司整体营业收入比例较低，具体情况请以公司披露的定期报告为准。 （文章来源：证券日报） ...

Core Viewpoint - The company, San Yuan Bio, has received a renewed certification as a high-tech enterprise from multiple governmental bodies in Shandong Province, indicating its continued status in the high-tech sector [2]. Group 1 - The announcement was made on February 9, highlighting the company's successful re-certification process [2]. - The re-certification follows the expiration of the previous high-tech enterprise certificate held by the company [2].

（文章来源：证券日报） 证券日报网讯 2月9日，城投控股发布公告称，公司2025年度实现营业总收入为1446227.90万元，同比增 长53.33%；归属于上市公司股东的净利润29046.38万元，同比增长19.67%。 ...

证券日报网讯 2月9日，聚辰股份在互动平台回答投资者提问时表示，认证进展请关注公司未来披露的 公告。 （文章来源：证券日报） ...

Core Viewpoint - Xizang Pharmaceutical's new drug, Xinhuasu, is positioned favorably in the domestic heart failure treatment market, facing limited competition as most rivals are still in clinical stages [2] Group 1: Market Position and Competition - Xinhuasu is currently the only approved biological drug for heart failure treatment in China, with Suzhou Landin's related products being the only competition that has been approved for market [2] - The company aims to consolidate and expand its market advantage through a three-pronged strategy: channel deepening, academic enhancement, and diversified product pipeline [2] Group 2: Strategic Initiatives - Channel Deepening and Terminal Coverage: Xinhuasu has entered nearly 7,000 hospital terminals, ensuring a broad coverage and stable foundation. The company plans to collaborate with commercial partners to integrate channel resources and expand into secondary hospitals and grassroots medical markets, thereby increasing terminal penetration [2] - Strengthening Evidence-Based Medical Support: The company has initiated exploratory research on evidence-based medicine for Xinhuasu, aiming to bolster the product's academic standing with robust clinical data and promote its application in more clinical scenarios [2] - Building a Diversified Product Pipeline: To reduce reliance on a single product, the company is actively pursuing strategic transformation by accelerating the market layout of its proprietary traditional Chinese medicine products and seeking new growth points through external collaborations and investments [2] Group 3: Market Potential - According to the 2023 Journal of Clinical Cardiovascular Diseases, there are approximately 12.1 million heart failure patients over the age of 25 in China, with about 3 million new cases each year. The current penetration rate of Xinhuasu remains low, indicating significant market potential amid an aging population and ongoing clinical demand [2]

Core Viewpoint - The company, Doli Technology, maintains a stable customer structure and demonstrates strong cooperation and business continuity with its main customer base, while actively seeking new market opportunities [2] Group 1: Customer Relationships - The company emphasizes the importance of maintaining existing customer relationships while also exploring potential collaborations with new clients [2] - There is a focus on systematic customer development and relationship management to expand the customer base [2] Group 2: Market Strategy - The company aims to enrich its product and service offerings, optimize customer structure, and enhance market layout to improve overall competitiveness and risk resistance [2] - The strategy is designed to achieve sustainable growth in the current market environment [2]

（文章来源：证券日报） 证券日报网讯 2月9日，三协电机发布公告称，公司2025年实现营业收入550739108.93元，同比增长 31.11%；归属于上市公司股东的净利润60183850.77元，同比增长6.83%。 ...

证券日报网讯 2月9日，立昂技术在互动平台回答投资者提问时表示，公司已披露的财务数据真实准 确，年度报告经会计师事务所审计验证，严格遵循《企业会计准则》编制，不存在虚假情形。未披露具 体客户及欠款单位信息，系基于保护商业秘密的合规要求，符合证监会信息披露豁免相关规定。公司应 收账款坏账准备计提充分、核销程序合规，相关财务处理均按规定执行，不存在通过计提销账调节业绩 的情况。 （文章来源：证券日报） ...